ImmunOs Therapeutics Secures Funding to Advance Cancer Trials
Recent Funding Boost for ImmunOs Therapeutics AG
ImmunOs Therapeutics AG, a pioneering biopharmaceutical company that utilizes a unique immune system modulating HLA-based technology, has successfully closed a Series C financing round, raising $11 million. This financial injection aims to further the development of innovative cancer therapies and strengthen its investor relationships.
Collaboration with Key Investors
This funding round saw significant backing from existing investors, including Gimv, Pfizer Ventures, Mission BioCapital, and BioMed Partners. New investor Double Point Ventures also joined, showcasing robust confidence in the company’s future. Notably, Steve Tregay, PhD, the Managing General Partner of Mission BioCapital, has taken a position on the Company’s Board of Directors, reflecting a strategic move to enhance governance and oversight.
Advancing Clinical Trials for IOS-1002
The funds garnered from this financing initiative will primarily support the ongoing Phase Ia dose escalation clinical trials of ImmunOs' lead candidate, IOS-1002. This groundbreaking investigational treatment is being evaluated as a monotherapy and in combination with Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), displaying its potential in a diverse approach to battling advanced solid tumors.
Significance of IOS-1002 in Cancer Treatment
IOS-1002 is a novel, multifunctional immunotherapy agent that uniquely targets several immune checkpoints, leveraging naturally occurring human leukocyte antigens (HLA) to drive a multifaceted immune response. This innovative therapy aims to activate both innate and adaptive immune cells, potentially transforming the tumor microenvironment and enhancing the effectiveness of existing immuno-oncological treatments like KEYTRUDA. The comparative nature of these treatments is pivotal as the sector continues to evolve.
Voices of Support from Key Players
Reinhard Ambros, the Executive Chairman of ImmunOs Therapeutics, expressed enthusiasm about the closing of this financing round. He emphasized the importance of both existing and new investors in validating the company’s mission and future potential. “The funding allows us to proceed with our lead program IOS-1002 as a novel therapy, addressing significant medical needs in cancer treatment,” he stated. Other executives from participating firms echoed his sentiments, expressing their excitement about being part of ImmunOs Therapeutics' journey toward advancing cancer therapies.
About ImmunOs Therapeutics AG
ImmunOs Therapeutics AG is at the forefront of biopharmaceutical innovation, channeling its research and development through a distinctive immune system modulating technology platform. It focuses on creating first-in-class therapeutics designed to target cancer and autoimmune diseases effectively. Their principal program involves a highly specialized HLA-fusion protein that engages selective receptors in the immune system, thereby enhancing the body's capability to eliminate tumor cells, setting a foundation for future breakthroughs in personalized cancer therapies.
Company Contact Information
For further information regarding their pioneering work, you can contact ImmunOs Therapeutics AG at their headquarters in Schlieren, Switzerland. They remain dedicated to making strides in the clinical development of IOS-1002 and exploring its vast potential to improve the lives of patients grappling with cancer.
Frequently Asked Questions
What recent funding has ImmunOs Therapeutics AG secured?
ImmunOs Therapeutics AG has raised $11 million in a Series C financing round to support their clinical trials.
Who are the key investors involved in this funding round?
The funding round included contributions from Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners, and new investors like Double Point Ventures.
What is the focus of the IOS-1002 therapy?
IOS-1002 is an advanced immunotherapy aimed at treating solid tumors by targeting multiple immune checkpoints.
How does IOS-1002 work?
This therapy activates both innate and adaptive immune responses, potentially enhancing the effectiveness of existing treatments such as KEYTRUDA.
Where is ImmunOs Therapeutics AG located?
The company is based in Schlieren, Switzerland, focusing on developing innovative treatments for cancer and autoimmune diseases.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.